Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 17Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 6Glioblastoma 5Triple Negative Breast Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Colorectal Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Tongue Neoplasms 1Thymoma 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-menopausal Breast Cancer 1

Interventions

Rituximab 47Cyclophosphamide 26fludarabine 13ibrutinib 12Doxorubicin 11Vincristine 10Etoposide 10Cytarabine 10Prednisone 9Bortezomib 9pembrolizumab 7fludarabine phosphate 6Lenalidomide 6Inotuzumab Ozogamicin 6obinutuzumab 5Mycophenolic Acid 5Melphalan 5Carmustine 5tositumomab I-131 4ibritumomab tiuxetan 4Tacrolimus 4Prednisolone 4Methotrexate 4Gemcitabine 4Bendamustine Hydrochloride 4Antilymphocyte Serum 4tocilizumab 3tazemetostat 3Whole-Body Irradiation 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell × NVP-BKM120 × Clear all
NCT02049541 2022-06-30

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
18 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡